Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients : data from the INC-EU Prospective Observational European Neutropenia Study

Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections. While reduction of chemotherapy dose or delay of the subsequent treatment cycle and, consequently, reduction of relative dose intensity (RDI) may limit myelotoxicity, these actions can also impact adversely on treatment outcome and should be avoided in adjuvant settings.